Advertisement

Medical Toxicology

, Volume 1, Issue 1, pp 3–11 | Cite as

Role of Repeated Oral Doses of Activated Charcoal in Clinical Toxicology

  • Susan M. Pond
Leading Article

Keywords

Charcoal Activate Charcoal Phenobarbitone Digitoxin Clinical Toxicology 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Belz GB, Bader H. Effect of oral charcoal on plasma levels of intravenous methyl proscillaridin. Klinische Wochenschrift 52: 1134–1135, 1974PubMedCrossRefGoogle Scholar
  2. Berg MJ, Berlinger WG, Goldberg MJ, Spector R, Johnson GF. Acceleration of the body clearance of phenobarbital by oral activated charcoal. New England Journal of Medicine 307: 642–644, 1982PubMedCrossRefGoogle Scholar
  3. Berlinger WG, Spector R, Goldberg MJ, Johnson GF, Quee CK, et al. Enhancement of theophylline clearance by oral activated charcoal. Clinical Pharmacology and Therapeutics 33: 351–354, 1983PubMedCrossRefGoogle Scholar
  4. Caldwell JH, Caldwell P, Murphy JW, Beachler CW. Intestinal secretion of digoxin in the rat. Naunyn Schmiedeberg’s Archives of Pharmacology 312: 271–275, 1980PubMedCrossRefGoogle Scholar
  5. Chung DC, Murphy JE, Taylor TW. In vivo comparison of the adsorption capacity of ‘superactive charcoal’ and fructose with activated charcoal and fructose. Journal of Toxicology, Clinical Toxicology 19(2): 219–224, 1982CrossRefGoogle Scholar
  6. Cooney DO. Activated charcoal. Antidotal and other medical uses, Marcel Dekker, New York, 1980Google Scholar
  7. Cooney D. A superactive charcoal for antidotal use in poisonings. Journal of Clinical Toxicology 11(4): 387–390, 1977CrossRefGoogle Scholar
  8. Cooney DO, Kane RP. Superactive charcoal adsorbs drugs as fast as standard antidotal charcoal. Journal of Clinical Toxicology 16(1): 123–125, 1980CrossRefGoogle Scholar
  9. Duggan DE, Kwan KC. Enterohepatic recirculation of drugs as a determinant of therapeutic ratio. Drug Metabolism Reviews 9: 21–41, 1979PubMedCrossRefGoogle Scholar
  10. Du Souich P, Caille G, La Rochelle P. Enhancement of nadolol elimination by activated charcoal and antibiotics. Clinical Pharmacology and Therapeutics 33: 585–590, 1983PubMedCrossRefGoogle Scholar
  11. Friedman EA, Feinstein EI, Beyer MM, Galonsky RS, Hirsch SR. Charcoal-induced lipid reduction in uremia. Kidney International 13 (Suppl. 8): S170–S176, 1978Google Scholar
  12. Gadgil SD, Damle SR, Advani SH, Vaidya AG. Effect of activated charcoal on the pharmacokinetics of high-dose methotrexate. Cancer Treatment Reports 66: 1169–1171, 1982PubMedGoogle Scholar
  13. Gal P, Miller A, McCur JD. Oral activated charcoal to enhance theophylline elimination in an acute overdose. Journal of the American Medical Association 251: 3130–3131, 1984PubMedCrossRefGoogle Scholar
  14. Garattini S. Hepatic toxicity with TCDD. Presented at National Academy of Sciences Workshop on Plans of Clinical and Epidemological Follow Up after Areawide Chemical Contamination, Washington, DC, March, 1980Google Scholar
  15. Goldberg MJ, Berlinger WG. Treatment of phenobarabital overdose with activated charcoal. Journal of the American Medical Association 247: 2400–2401, 1982PubMedCrossRefGoogle Scholar
  16. Goldberg MJ, Berlinger WG, Park GD. Activated charcoal in phenobarbital overdose. Journal of the American Medical Association 253: 1120–1121, 1985PubMedCrossRefGoogle Scholar
  17. Goldberg MJ, Park GD, Spector R, Fischer LJ, Feldman RD. Lack of effect of oral activated charcoal on imipramine clearance. Clinical Pharmacology and Therapeutics 38: 350–353, 1985PubMedCrossRefGoogle Scholar
  18. Guzelian PS. New approaches for treatment of humans exposed to a slowly excreted environmental chemical (chlordecone). A. Gastroenterologie 22: 16–20, 1984Google Scholar
  19. Hayden JW, Comstock EG. Use of activated charcoal in acute poisoning. Clinical Toxicology 8: 515–533, 1975PubMedCrossRefGoogle Scholar
  20. Javaid KA, El-Mabrouk BH. In vitro absorption of phenobarbital onto activated charcoal. Journal of Pharmaceutical Sciences 72: 82–85, 1983PubMedCrossRefGoogle Scholar
  21. Kärkkäinen S, Neuvonen PJ. Effect of oral charcoal and urine pH on sotalol pharmacokinetics. International Journal of Pharmacology, Therapy and Toxicology 22(8): 441–446, 1984Google Scholar
  22. Kärkkäinen S, Neuvonen PJ. Effect of oral charcoal and urine pH on dextropropoxyphene pharmacokinetics. International Journal of Pharmacology, Therapy and Toxicology 23(4): 219–225, 1985Google Scholar
  23. Klaassen CD. Biliary excretion of xenobiotics. CRC Critical Reviews in Toxicology 4: 1–30, 1975PubMedGoogle Scholar
  24. Kolibash AJ, Kramer WG, Reuing RH, Caldwell JH. Marked decline in serum digoxin concentration during an episode of severe diarrhea. American Heart Journal 94: 805–807, 1977CrossRefGoogle Scholar
  25. Lake KD, Brown DC, Peterson CD. Digoxin toxicity: enhanced systemic elimination during oral activated charcoal therapy. Pharmacotherapy 4: 161–163, 1984PubMedGoogle Scholar
  26. Lalonde RS, Deshpande R, Hamilton PP, McLean WM, Greenway DC. Acceleration of digoxin clearance by activated charcoal. Clinical Pharmacology and Therapeutics 37: 367–371, 1985PubMedCrossRefGoogle Scholar
  27. Lenz K, Morz R, Kleinberger G, Pointner H, Druml W, et al. Effect of gut lavage on phenobarbital elimination in rats. Journal of Toxicology — Clinical Toxicology 20: 147–157, 1983PubMedCrossRefGoogle Scholar
  28. Levy G. Gastrointestinal clearance of drugs with activated charcoal. New England Journal of Medicine 387: 676–678, 1982CrossRefGoogle Scholar
  29. Mahutte CK, True RJ, Michiels TN, Berman JN, Light RW. Increased serum theophylline clearance with orally administered activated charcoal. American Review of Respiratory Disease 128: 820–822, 1983PubMedGoogle Scholar
  30. Neuvonen PJ. Clinical pharmacokinetics of oral activated charcoal in acute intoxications. Clinical Pharmacokinetics 7: 465–489, 1982PubMedCrossRefGoogle Scholar
  31. Neuvonen PJ, Elonen E. Effect of activated charcoal on absorption and elimination of phenobarbitone, carbamazepine and phenylbutazone in man. European Journal of Clinical Pharmacology 17: 51–57, 1980PubMedCrossRefGoogle Scholar
  32. Neuvonen PJ, Karkkainen S. Effects of charcoal, sodium bicarbonate and ammonium chloride on chlorpropamide kinetics. Clinical Pharmacology and Therapeutics 33: 386–393, 1983PubMedCrossRefGoogle Scholar
  33. Neuvonen PJ, Elonen E, Mattila MJ. Oral activated charcoal and dapsone elimination. Clinical Pharmacology and Therapeutics 27: 823–827, 1980PubMedCrossRefGoogle Scholar
  34. Olkkola KT, Neuvonen PJ. Do gastric contents modify antidotal efficacy of oral activated charcoal? British Journal of Clinical Pharmacology 18: 663–669, 1984PubMedCrossRefGoogle Scholar
  35. Park GD, Radomski L, Goldberg MJ, Spector R, Johnson GF, et al. Effects of size and frequency of oral doses of charcoal on theophylline clearance. Clinical Pharmacology and Therapeutics 34: 663–666, 1983PubMedCrossRefGoogle Scholar
  36. Park GD, Spector R, Goldberg MJ, Johnson GF, Feldman R, et al. Effect of the surface area of activated charcoal on theophylline clearance. Journal of Clinical Pharmacology 24(7): 289–292, 1984PubMedGoogle Scholar
  37. Pollack MM, Dunbar BS, Holbrook PR, Fields AI. Aspiration of activated charcoal and gastric contents. Annals of Emergency Medicine 10: 528–529, 1981PubMedCrossRefGoogle Scholar
  38. Pond SM. Diuresis dialysis and haemoperfusion: indications and benefits. Emergency Medicine Clinics of North America 2: 29–45, 1984PubMedGoogle Scholar
  39. Pond S, Jacobs M, Marks J, Garner J, Goldschlager N, et al. Treatment of digitoxin overdose with oral activated charcoal. Lancet 2: 1177–1178, 1981PubMedCrossRefGoogle Scholar
  40. Pond SM, Olson KR, Osterloh JD, Tong TG. Randomised study of the treatment of phenobarbital overdose with repeated doses of activated charcoal. Journal of the American Medical Association 251: 3104–3108, 1984.PubMedCrossRefGoogle Scholar
  41. Pond SM, Osterloh JD, Olson KR, Tong TG. Activated charcoal and phenobarbital overdose. Journal of the American Medical Association 253: 1121, 1985CrossRefGoogle Scholar
  42. Radomski L, Park GD, Goldberg MJ, Spector R, Johnson GF, et al. Model for theophylline overdose treatment with oral activated charcoal. Clinical Pharmacology and Therapeutics 35: 402–408, 1984PubMedCrossRefGoogle Scholar
  43. Reissel P, Manninen V. Effect of administration of activated charcoal and fibre on absorption, excretion and steady state tween clinical condition and blood barbiturate levels. American Journal of Clinical Pathology 24: 1133–1138, 1954Google Scholar
  44. Trudnowski R, Gessner T. Mechanism for gastric accumulation of meperidine and effect of antacid. Canadian Anaesthetists’ Society Journal 27: 496–499, 1980PubMedCrossRefGoogle Scholar
  45. True RJ, Berman JN, Mahutte CK. Treatment of theophylline toxicity with oral activated charcoal. Critical Care Medicine 12: 113–114, 1984PubMedCrossRefGoogle Scholar
  46. Winchester JF, Gelfand MC, Knepshield JH, Shreiner GE. Dialysis and hemoperfusion of poisons and drugs — update. Transactions of the American Society of Artificial and Internal Organs 23: 762–842, 1977 blood levels of digoxin and digitoxin. Evidence for intestinal secretion of the glycosides. Acta Medica Scandinavica Suppl. 668: 88–90, 1982CrossRefGoogle Scholar
  47. Rosenberg J, Benowitz L, Pond SM. Pharmacokinetics of drug overdose. Clinical Pharmacokinetics 6: 161–192, 1981PubMedCrossRefGoogle Scholar
  48. Rozman K, Rozman T, Greim H. Stimulation of nonbiliary, intestinal excretion of hexachlorobenzene in rhesus monkeys by mineral oil. Toxicology and Applied Pharmacology 70: 255–261, 1983PubMedCrossRefGoogle Scholar
  49. Sunshine I, Hackett ER. Barbiturate studies. II. Correlation beGoogle Scholar
  50. Yasuhara M, Kurosaki Y, Kimura T, Sezaki H. Drug elimination function of rat small intestine: metabolism and intraluminal excretion. Biochemical Pharmacology 33: 3132–3136, 1984CrossRefGoogle Scholar

Copyright information

© ADIS Press Limited 1986

Authors and Affiliations

  • Susan M. Pond
    • 1
  1. 1.Department of Medicine, Princess Alexandra HospitalUniversity of QueenslandBrisbaneAustralia

Personalised recommendations